US OptionsDetailed Quotes
SCLX241220C500
- 0.05
- -0.10-66.67%
15min DelayClose Dec 13 16:00 ET
0.07High0.05Low
0.07Open0.15Pre Close76 Volume219 Open Interest0.50Strike Price382.00Turnover173.54%IV8.48%PremiumDec 20, 2024Expiry Date0.01Intrinsic Value100Multiplier6DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type0.5724Delta3.3706Gamma10.15Leverage Ratio-0.0038Theta0.0000Rho5.81Eff Leverage0.0003Vega
Scilex Holding Stock Discussion
Sign in to post a comment
$Scilex Holding (SCLX.US)$ Reuters· just
Scilex Holding Company Announces $17 Million Registered Direct Offering
Scilex Holding Company Announces $17 Million Registered Direct Offering
4
$Scilex Holding (SCLX.US)$ $Denali Capital Acquisition Corp (DECA.US)$ Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
4 MINUTES AGO, 4:00 PM EST
VIA GLOBENEWSWIRE
4 MINUTES AGO, 4:00 PM EST
VIA GLOBENEWSWIRE
$Scilex Holding (SCLX.US)$
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials Conducted by NeuroBiogen for KDS2010, a Novel Oral Tablet Recently Synthesized Potent, Selective, and Reversible Monoamine Oxidase B inhibitor
Wednesday, 11th December at 7:30 am
• The ongoing obesity Phase 2 tr...
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials Conducted by NeuroBiogen for KDS2010, a Novel Oral Tablet Recently Synthesized Potent, Selective, and Reversible Monoamine Oxidase B inhibitor
Wednesday, 11th December at 7:30 am
• The ongoing obesity Phase 2 tr...
1
$Scilex Holding (SCLX.US)$ Reuters· 2 mins ago
Scilex Holding Company Enters Into a Binding Term Sheet for a Joint Venture With Ipmc and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-in-Class Novel Oral Tablet for the Treatment of Obesity and Neurodegenerative Diseases Including Alzheimer’s Disease
Scilex Holding Company Enters Into a Binding Term Sheet for a Joint Venture With Ipmc and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-in-Class Novel Oral Tablet for the Treatment of Obesity and Neurodegenerative Diseases Including Alzheimer’s Disease
1
$Scilex Holding (SCLX.US)$
Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and Neurodegenerative Diseases Including Alzheimer's Disease
Tuesday, 10th December at 7:00 am
• The joint venture, Scilex Bio ("Scilex Bio JV"), will have global development and commercialization rights for a Phase 2 clin...
Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and Neurodegenerative Diseases Including Alzheimer's Disease
Tuesday, 10th December at 7:00 am
• The joint venture, Scilex Bio ("Scilex Bio JV"), will have global development and commercialization rights for a Phase 2 clin...
No comment yet
《Only》鑫鑫 : Good news?
Trytosaveabit OP 《Only》鑫鑫 : Short term absolutely not! Longer term yes!
《Only》鑫鑫 : It seems like the news is for the purpose of consolidation.
Trytosaveabit OP 《Only》鑫鑫 : It’s possible? They just extended the merger timeframe again! So that may play into it as well?